Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
Future Oncol
; 10(12): 1925-39, 2014 Oct.
Article
en En
| MEDLINE
| ID: mdl-24856155
ABSTRACT
The anaplastic lymphoma kinase (ALK) gene plays a key role in the pathogenesis of selected tumors, including non-small-cell lung cancer (NSCLC). Patients with ALK-rearranged NSCLC are initially sensitive to the ALK inhibitor crizotinib but eventually become resistant, limiting its therapeutic potential. Ceritinib is an oral second-generation ALK inhibitor with greater preclinical antitumor potency than crizotinib in ALK-positive NSCLC. A Phase I trial of ceritinib in ALK-positive tumors demonstrated good activity in patients with advanced NSCLC, including those who had progressed on crizotinib. Adverse events are similar to those seen with other ALK tyrosine kinase inhibitors and are generally manageable. Ongoing trials are evaluating ceritinib in patients with ALK-rearranged NSCLC treated with prior chemotherapy and/or crizotinib.
Palabras clave
Texto completo:
1
Banco de datos:
MEDLINE
Asunto principal:
Pirimidinas
/
Sulfonas
/
Carcinoma de Pulmón de Células no Pequeñas
/
Neoplasias Pulmonares
/
Antineoplásicos
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Future Oncol
Año:
2014
Tipo del documento:
Article
País de afiliación:
Bélgica